Cat. No.: X23-10-ZQ428
JAK inhibitor Upadacitinib, Purity ≥98%
Synonym: Upadacitinib; 1310726-60-3; ABT-494; Rinvoq; Upadacitinib anhydrous; 4RA0KN46E0; UNII-4RA0KN46E0; JAK inhibitor
- MDL: MFCD30502663
- CAS Number: 1310726-60-3
- Compound CID: 58557659
Product Size
2 mg; 5 mg; 10 mg; 25 mg; 50 mg
Properties
Description
Upadacitinib, soluble in DMSO and ethanol and insoluble in water, is an available JAK small molecule inhibitor with potential antineoplastic activity. It targets JAK1, JAK2, JAK3, and Tyk2.
Molecular Formula
C17H19F3N6O
Targets
JAK1: 0.043 μM; JAK2: 0.2 μM; JAK3: 2.3 μM; Tyk2: 4.7 μM
Solubility
DMSO: 66 mg/mL (173.51 mM); Water: Insoluble; Ethanol: 66 mg/mL (173.51 mM)
Identity
Confirmed by NMR/HPLC/MS.
Applications
Upadacitinib can be used in research targeting JAK1 for treating autoimmune diseases.
Related Products
-
JAK inhibitor JAK/HDAC-IN-1, Purity ≥98%
-
JAK inhibitor 1,2,3,4,5,6-Hexabromocyclohexane, Purity ≥98%
-
JAK inhibitor Abrocitinib, Purity ≥98%
-
JAK inhibitor AZ-3, Purity ≥98%
-
JAK inhibitor AZ-960, Purity ≥98%
-
JAK inhibitor AZD1480, Purity ≥98%
Quick Links